Blackstone Life Sciences (BXLS)
We combine scale capital with deep clinical development expertise to help advance innovative medicines and technologies with the potential to transform patients’ lives. Our team invests across the life cycle of companies and products in a range of therapeutic areas.
114
Medicines Brought to Market
24
MDs or PhDs on the Team
85%
Phase 3 Success Rate*
WHAT WE DO
We partner with pharmaceutical, biotech and medical technology companies to fund products that address unmet medical needs and have the potential to improve the quality of life for patients around the world.
Filling a Void
Blackstone Life Sciences (BXLS) fills a critical void in the industry. While the life sciences are seeing unprecedented innovation driven by rapid advancements in science and technology, there is a lack of funding necessary to bring medicines and healthcare technologies to market. We invest in and partner with pharmaceutical, biotechnology and medical technology companies to help meet this need.
Expertise and Scale
BXLS combines clinical, commercial and operational expertise with Blackstone’s knowledge and global network, access to capital, resources and infrastructure. We commit our skill and scale to select, fund and advance what we believe to be the most promising life science products and companies through hands-on involvement and directly applied expertise.
Managing Risk
We seek to deliver value for investors by focusing on areas where we can apply our deep clinical and commercial domain expertise. By investing in promising candidates in late-stage development, we aim to make a positive impact on the most people with the lowest clinical risk.
Case Studies
The Blackstone Life Sciences team of employees, Senior Advisors and Development Company personnel is responsible — both in its current capacity and prior experiences— for bringing 111 medicines to market in 17 different therapeutic areas.
Sanofi Partnership
In March 2022, Blackstone Life Sciences announced a partnership with Sanofi to advance the development of Sarclisa®, a promising treatment for patients with multiple myeloma (MM), a type of blood cancer. The partnership will focus on developing a subcutaneous form of the treatment to make its delivery more convenient for patients with MM. This partnership showcases the flexible capital and deep expertise that enables BXLS to partner with leading pharmaceutical companies to advance potentially lifesaving products.
Alnylam
In April 2020, BXLS led a $2 billion strategic collaboration with Alnylam anchored around the acquisition of a royalty interest in inclisiran, an innovative product, which will potentially bring new benefits to patients with high cholesterol — a major risk factor for cardiovascular disease. The drug began receiving regulatory approvals globally in the fall of 2021.
Anthos Therapeutics, Inc.
In February 2019, BXLS invested in Anthos Therapeutics, Inc., in partnership with Novartis, to advance next-generation targeted therapies for high-risk cardiovascular patients. This investment will potentially help meet a large, unmet need for next-generation antithrombotic therapies for patients that are underserved by more conventional medicines. According to the American Heart Association, thrombotic disorders cause nearly 500,000 deaths each year.
Note: All figures as of December 31 2022, unless otherwise indicated.
*Evaluate 2020 data and estimates and medicines brought to market by BXLS and development company employees and Senior Advisors (Nick Galakatos, Emmett Cunningham, Kurt Wheeler, Bob DeBenedetto, Barry Gertz, Dennis Henner, Ed Scolnick, Jeff Chodakewitz, Kiran Reddy, Francois Nader, Olivier Brandicourt) while they worked at prior employers. The development of a medicine involves many professionals. The degree of involvement by a given BXLS professional varies medicine to medicine. Therefore, the performance shown reflects the contributions of a number of professionals and may not be indicative of any individual’s contributions to the transactions. The number of developed medicines is measured when a drug is approved in any jurisdiction. Senior Advisors are not employees of Blackstone.
“We support promising companies and products, providing flexible capital and clinical expertise to advance innovation and improve outcomes for patients.”
NICK GALAKATOS, PHDGLOBAL HEAD OF LIFE SCIENCES
Updates from Life Sciences
CNBC
Big Bets on Biotech
Nick Galakatos, Global Head of Blackstone Life Sciences, discussed our “building-beaker-bedside” model at CNBC’s Healthy Returns Summit. We invest in promising new treatments, real estate for critical research and logistics facilities to help innovative therapies reach patients faster.
BioSpace
Sanofi Rebounds with $329M Blackstone Infusion for Multiple Myeloma Drug
BioSpace covers Blackstone’s partnership with Sanofi, which aims to accelerate the pharma company’s ability to provide the subcutaneous formulation of multiple myeloma drug Sarclisa to patients in a more innovative and convenient manner. This investment exemplifies BXLS’ commitment to providing flexible capital to help advance vital medicines.
WSJ
How Private Capital Can Yield “Healthy” Returns
The life sciences industry faces severe funding gaps that stand in the way of delivering life-saving medicines and technologies to patients. Blackstone’s expertise and capital can help address this need.